|
WO2021062164A1
|
|
Characterization of gene therapy viral particles using size exclusion chromatography and multi-angle light scattering technologies
|
|
WO2021055497A1
|
|
Cnp variants and conjugates thereof
|
|
WO2021042020A1
|
|
Methods for treating cln2 disease in pediatric subjects
|
|
WO2021030411A1
|
|
Hydrophobic peptide salts for extended release compositions
|
|
WO2020257487A1
|
|
Glycolate oxidase inhibitors for the treatment of disease
|
|
US2020362368A1
|
|
Methods of redosing gene therapy vectors
|
|
WO2020028221A1
|
|
Ceramide galactosyltransferase inhibitors for the treatment of disease
|
|
SG11202010832YA
|
|
Stable expression of aav vectors in juvenile subjects
|
|
TW202005978A
|
|
Novel liver targeting adeno-associated viral vectors
|
|
AU2019265560A1
|
|
Methods of treating phenylketonuria
|
|
AR114070A1
|
|
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF A DISEASE
|
|
WO2019104011A1
|
|
Ceramide galactosyltransferase inhibitors for the treatment of disease
|
|
KR20200003160A
|
|
Improved Lentivirus for Transduction of Hematopoietic Stem Cells
|
|
TW201829381A
|
|
Histone Deacetylase Inhibitors
|
|
US2019322676A1
|
|
Ceramide galactosyltransferase inhibitors for the treatment of disease
|
|
SG11201811603WA
|
|
Novel adeno-associated virus capsid proteins
|
|
TW201802073A
|
|
Ceramide galactosyltransferase inhibitors for the treatment of disease
|
|
KR20180114199A
|
|
Targeted therapeutic lysozyme enzyme fusion proteins, related formulations and uses thereof
|
|
WO2017100400A2
|
|
Use of c-type natriuretic peptide variants to treat osteoarthritis
|
|
US2017050984A1
|
|
Histone deacetylase inhibitors
|
